1-7 of 7
Jeffrey Sosman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Curtis H. Kugel, III, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al-Rohil, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell Fane, Michael J. Allegrezza, Nikolaos Svoronos, Vinit Kumar, Daniel Y. Wang, Rajasekharan Somasundaram, Siwen Hu-Lieskovan, Alpaslan Ozgun, Meenhard Herlyn, Jose R. Conejo-Garcia, Dmitry Gabrilovich, Erica L. Stone, Theodore S. Nowicki, Jeffrey Sosman, Rajat Rai, Matteo S. Carlino, Georgina V. Long, Richard Marais, Antoni Ribas, Zeynep Eroglu, Michael A. Davies, Bastian Schilling, Dirk Schadendorf, Wei Xu, Ravi K. Amaravadi, Alexander M. Menzies, Jennifer L. McQuade, Douglas B. Johnson, Iman Osman, Ashani T. Weeraratna
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5347–5356.
https://doi.org/10.1158/1078-0432.CCR-18-1116
Published: 01 November 2018
View article titled, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Open the PDF for Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations in another window
Includes: Supplementary data
Journal Articles

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Matthew J. Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas Amler, Yibing Yan, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5238–5245.
https://doi.org/10.1158/1078-0432.CCR-17-0172
Published: 31 August 2017
View article titled, Gene Expression Profiling in <em>BRAF</em>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Open the PDF for Gene Expression Profiling in <em>BRAF</em>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Kim Margolin, Michael B. Atkins, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith, II, Joseph I. Clark, Joseph Baar, Jeffrey Sosman, Jeffrey Weber, Chetan Lathia, Janice Brunetti, Frank Cihon, Brian Schwartz
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3312–3319.
https://doi.org/10.1158/1078-0432.CCR-06-1341
Published: 01 June 2007
View article titled, Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer
Open the PDF for Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer in another window
Journal Articles

The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study

Kenneth R. Hande, Anne Hagey, Jordan Berlin, Yingna Cai, Kysa Meek, Hiro Kobayashi, A. Craig Lockhart, Diane Medina, Jeffrey Sosman, Gary B. Gordon, Mace L. Rothenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2834–2840.
https://doi.org/10.1158/1078-0432.CCR-05-2159
Published: 04 May 2006
View article titled, The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study
Open the PDF for The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study in another window
Journal Articles

Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma

Thomas F. Gajewski, Jeffrey Sosman, Stanton L. Gerson, Lili Liu, Eileen Dolan, Shang Lin, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7861–7865.
https://doi.org/10.1158/1078-0432.CCR-05-0060
Published: 08 November 2005
View article titled, Phase II Trial of the <em>O</em><sup>6</sup>-Alkylguanine DNA Alkyltransferase Inhibitor <em>O</em><sup>6</sup>-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma
Open the PDF for Phase II Trial of the <em>O</em><sup>6</sup>-Alkylguanine DNA Alkyltransferase Inhibitor <em>O</em><sup>6</sup>-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma in another window
Journal Articles

A Phase I Study of CNI-1493, an Inhibitor of Cytokine Release, in Combination with High-Dose Interleukin-2 in Patients with Renal Cancer and Melanoma

Michael B. Atkins, Bruce Redman, James Mier, Jared Gollob, Jeffrey Weber, Jeffrey Sosman, Bret L MacPherson, Terry Plasse
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 486–492.
Published: 01 March 2001
View article titled, A Phase I Study of CNI-1493, an Inhibitor of Cytokine Release, in Combination with High-Dose Interleukin-2 in Patients with Renal Cancer and Melanoma
Open the PDF for A Phase I Study of CNI-1493, an Inhibitor of Cytokine Release, in Combination with High-Dose Interleukin-2 in Patients with Renal Cancer and Melanoma in another window
Journal Articles

Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

Janice P. Dutcher, Theodore Logan, Michael Gordon, Jeffrey Sosman, Geoffrey Weiss, Kim Margolin, Terry Plasse, James Mier, Michael Lotze, Joseph Clark, Michael Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3442–3450.
Published: 01 September 2000
View article titled, Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study
Open the PDF for Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study in another window